These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23559876)

  • 1. Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review.
    Hoch JS; Sabharwal M
    Curr Oncol; 2013 Apr; 20(2):121-4. PubMed ID: 23559876
    [No Abstract]   [Full Text] [Related]  

  • 2. Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.
    Hoch JS; Brown MB; McMahon C; Nanson J; Rozmovits L
    Curr Oncol; 2014 Oct; 21(5):263-6. PubMed ID: 25302034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
    Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
    Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using a rapid environmental scan methodology to map country-level global health research expertise in Canada.
    Nagi R; Rogers Van Katwyk S; Hoffman SJ
    Health Res Policy Syst; 2020 Apr; 18(1):37. PubMed ID: 32272941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reluctant partner: Canada's relationship with the Pan American Health Organization (PAHO)].
    Dmitrienko K
    Hist Cienc Saude Manguinhos; 2006; 13(3):717-32. PubMed ID: 17117515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.
    McDonald H; Charles C; Elit L; Gafni A
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27489586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
    Niraula S
    Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.
    Rocchi A; Mills F
    J Popul Ther Clin Pharmacol; 2018 Aug; 25(2):e12-e22. PubMed ID: 30725539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 10. Canada's contribution to global research in cardiovascular diseases.
    Nguyen HV; de Oliveira C; Wijeysundera HC; Wong WW; Woo G; Grootendorst P; Liu PP; Krahn MD
    Can J Cardiol; 2013 Jun; 29(6):742-6. PubMed ID: 23219608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canada's health system.
    Davies BJ
    Croat Med J; 1999 Jun; 40(2):280-6. PubMed ID: 10234072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canada's international response to HIV during times of global transition: a qualitative inquiry.
    Nixon S
    Curr HIV Res; 2011 Apr; 9(3):194-201. PubMed ID: 21457132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canada's 2003 renewed drug strategy--an evidence-based review.
    DeBeck K; Wood E; Montaner J; Kerr T
    HIV AIDS Policy Law Rev; 2006 Dec; 11(2-3):1, 5-12. PubMed ID: 17373058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulating compassion: an overview of Canada's federal medical cannabis policy and practice.
    Lucas PG
    Harm Reduct J; 2008 Jan; 5():5. PubMed ID: 18226254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nutritional quality of the food choices of Canadian children.
    Hack S; Jessri M; L'Abbé MR
    BMC Nutr; 2021 May; 7(1):16. PubMed ID: 34049592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming Canada's role in global cancer control.
    Rodin D; Dare AJ; Booker R; Booth C; Bryant H; Ginsburg O; Giuliani M; Gospodarowicz M; Gupta S; Hammad N; Rosberger Z; Sutcliffe S; Earle CC
    Lancet Oncol; 2021 Sep; 22(9):e400-e409. PubMed ID: 34478676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Charles H. Best, the Canadian Red Cross Society, and Canada's first national blood donation program.
    Kapp RW
    Can Bull Med Hist; 1995; 12(1):27-46. PubMed ID: 11609096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canada and access to medicines in developing countries: intellectual property rights first.
    Lexchin J
    Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whose feminism(s)? Overseas partner organizations' perceptions of Canada's Feminist International Assistance Policy.
    Rao S; Tiessen R
    Int J; 2020 Sep; 75(3):349-366. PubMed ID: 33149367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
    Lexchin J
    BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.